ArticleCommunications biology2021
Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- The role of theTranslational cancer research · 2026Article
- Prognostic role of CDCA3 in lung adenocarcinoma with immune infiltration.Scientific reports · 2026Article
- Construction of an E3 Ubiquitin Ligase Gene Model to Predict the Prognosis of Idiopathic Pulmonary Fibrosis Patients Using Integrated Bioinformatics Analysis.Current medicinal chemistry · 2026Article
- Single-cell-derived ferroptosis signature predicts prognosis and therapy response in esophageal squamous cell carcinoma.Frontiers in oncology · 2026Article
- Hypoxia-triggered autophagy modulates cisplatin resistance in non-small cell lung Cancer via EIF2AK3-dependent PI3K/AKT signaling and mTOR-independent mechanisms.Cell death discovery · 2025Article
- PRC1, CDCA3, and CDC20 are upregulated and Treg numbers are decreased in canine massive hepatocellular carcinoma.BMC veterinary research · 2025Article
- The inner nuclear membrane protein, Banf1, has an essential role in triple negative breast cancer cell proliferation and survival.Scientific reports · 2025Article
- RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.Oncology reports · 2025Article
- Identification of N6-methyladenosine-associated ferroptosis biomarkers in cervical cancer.Hereditas · 2025Article
- CDCA3 Regulates Tumor-Associated Macrophages Polarize to Promote the Malignant Progression of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity.Science advances · 2024Article
- Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.British journal of cancer · 2024Article
- Targeting the COMMD4-H2B protein complex in lung cancer.British journal of cancer · 2023Article
- The molecular details of a novel phosphorylation-dependent interaction between MRN and the SOSS complex.Protein science : a publication of the Protein Society · 2023Article
- Structural investigation of CDCA3-Cdh1 protein-protein interactions using in vitro studies and molecular dynamics simulation.Protein science : a publication of the Protein Society · 2023Article
- CK2 and the Hallmarks of Cancer.Biomedicines · 2022Review
- Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance.Cell death & disease · 2022Article
- Pan-cancer analysis identifiesTranslational cancer research · 2022Article
- Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.BioMed research international · 2022Review
- Silmitasertib-induced macropinocytosis promoting DDP intracellular uptake to enhance cell apoptosis in oral squamous cell carcinoma.Drug delivery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy remains the cornerstone of treatment for most non-small cell lung cancer (NSCLC) cases either as maintenance therapy or in combination with immunotherapy. However, resistance remains a primary issue. Our findings point to the possibility of exploiting levels of cell division cycle associated protein-3 (CDCA3) to improve response of NSCLC tumours to therapy. We demonstrate that in patients and in vitro analyses, CDCA3 levels correlate with measures of genome instability and platinum sensitivity, whereby CDCA3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.